Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Innate Pharma Sa > Profile

Innate Pharma Sa (IPHA)

Market is closed
Sector: Biological Products, (No Disgnostic Substances)

Hedge Fund Popularity

13F filing is ongoing

Hedge Fund Holdings
Filing Period:
Last update:
No. Hedge Fund Shares Value Activity % Port
1.
Lion Point

Didric Cederholm

 81,151 $149,318 0.71%
2.
Citadel Investment Group

Ken Griffin

 12,441 $22,891 0%
3.
Millennium Management

Israel Englander

 0 $0 0%
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
No. Name Shares Value % Port
1.
Farther Finance Advisors, Llc
 10 $16 0%
2.
Gamma Investing Llc
 9 $15 0%
News See All
Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?

Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?

Innate Pharma S.A. (NASDAQ:IPHA) reported a €19.6 million first-half net loss on September 17, following the closing of its lacutamab partnership with Sobi a day earlier.

Keep Reading →

September 22nd, 2026 - Hedge Funds News

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2026 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2026 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2026 Earnings Call Transcript May 13, 2026Innate Pharma S.A. beats earnings expectations. Reported EPS is $-0.34627, expectations were $-0.34918.

Keep Reading →

May 14th, 2026 - News Transcripts

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2025 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2025 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2025 Earnings Call Transcript November 13, 2025Innate Pharma S.A. beats earnings expectations. Reported EPS is $-0.24551, expectations were $-0.32845.

Keep Reading →

November 18th, 2025 - News Transcripts

Innate Pharma S.A. (NASDAQ:IPHA) Q2 2025 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q2 2025 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q2 2025 Earnings Call Transcript September 17, 2025Innate Pharma S.A. beats earnings expectations. Reported EPS is $-0.2963, expectations were $-0.32845.

Keep Reading →

September 18th, 2025 - News Transcripts

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2025 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2025 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2025 Earnings Call Transcript May 13, 2025 Operator: Hello, and thank you for standing by. My name is Lacey, and I will be your conference operator today.

Keep Reading →

May 14th, 2025 - News Transcripts

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Call Transcript March 27, 2025Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 EPS, expectations were $-0.26681.

Keep Reading →

March 29th, 2025 - News Transcripts

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2024 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2024 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Hello and thank you for standing by. My name is Regina and will be your conference operator today.

Keep Reading →

November 14th, 2024 - News Transcripts

Innate Pharma S.A. (NASDAQ:IPHA) Q2 2024 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q2 2024 Earnings Call Transcript

Innate Pharma S.A.

Keep Reading →

September 13th, 2024 - News Transcripts

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2024 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2024 Earnings Call Transcript

Innate Pharma S.A.

Keep Reading →

May 15th, 2024 - News Transcripts

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript March 21, 2024 Innate Pharma S.A.

Keep Reading →

March 22nd, 2024 - News Transcripts

Click here to See All News
Insider Monkey Quarterly Strategy
+599.2% Insider Monkey Quarterly Strategy
+227% Benchmark50% S&P 500 ETF and 50% Russell 2000 ETF
500%
250%
0%

Returns since its inception in May 2014 (through June 2, 2026)

Subscribe Now

30 day money back guarantee. Cancel anytime.

Past performance does not guarantee future returns. Click to see how the portfolio is constructed.